en · de · es · pt
peptide-index.peptides5388.com › Data › Background And Receptor Mechanism — Common Mistakes

Background And Receptor Mechanism — Common Mistakes

By Editorial Desk · published 2026-07-04 · last reviewed 2026-08-01 · Data

REV-ERB comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

SR9009 Handling and Quality Control

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

Related pages on this site

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Reference notes

where N is 100, nx is the percentage of sequences with residue x (e.g. methionine) at position i, and px corresponds to the approximate distribution of amino acid x in all positions among all sequenced proteins. The summation runs over all 20 amino acids. After ΔGistat is computed, the conservation for position i in a subalignment produced after a perturbation of amino acid distribution at j (ΔGi | δjstat) is taken. Statistical coupling energy, denoted ΔΔGi, jstat, is simply the difference between these two values. That is:

== History == In the 1990s, clinafloxacin showed promise as a novel, broad-spectrum fluoroquinolone antibiotic. However, further clinical trials raised serious concerns regarding its safety in humans, citing dangerously low blood sugar, drug-induced light sensitivity, and multiple drug-drug interactions.

Bismuth (83Bi) has 41 known isotopes, ranging from 184Bi to 224Bi. Bismuth has one nearly stable isotope but no stable isotopes, the standard atomic weight can be given from that isotope, bismuth-209. Though it is now known to be radioactive, it may still be considered practically stable because it has a half-life of 2.01×1019 years, which is more than a billion times the age of the universe. As a result, it is the longest lived known alpha emitter. Bismuth-209 is also the heaviest nearly stable isotope, with the longest lived isotope with a greater atomic weight being thorium-232. Besides 209Bi, the most stable bismuth radioisotopes are 210mBi with a half-life of 3.04 million years, 208Bi with a half-life of 368,000 years and 207Bi, with a half-life of 31.22 years, none of which occur in nature. All other isotopes have half-lives under 15 days, most under two hours. Of naturally occurring radioisotopes, the most stable is radiogenic 210Bi with a half-life of 5.012 days. 210mBi is unusual for being a nuclear isomer with a half-life many orders of magnitude longer than that of the ground state.

Sources: en.wikipedia.org

Notes from published material

== Thermodynamics and inorganic chemistry == An alternative quantitative approach to inorganic chemistry focuses on energies of reactions. This approach is highly traditional and empirical, but it is also useful. Broad concepts that are couched in thermodynamic terms include redox potential, acidity, phase changes. A classic concept in inorganic thermodynamics is the Born–Haber cycle, which is used for assessing the energies of elementary processes such as electron affinity, some of which cannot be observed directly.

Some historians explain the reluctance to declare independence as a "mask of Ferdinand VII": that is, that Patriot leaders felt they needed to claim loyalty to the deposed monarch to prepare the masses for the radical change that full independence would eventually entail. Nevertheless, even areas such as Río de la Plata and Chile, which more or less maintained de facto independence from the peninsular authorities, did not declare independence until quite a few years later, in 1816 and 1818, respectively. Overall, despite achieving formal or de facto independence, many regions of Spanish America were marked by nearly continuous wars, which lasted well into the 1820s. In Mexico, where the junta movement had been stopped in its early stages by a coalition of peninsular merchants and government officials, efforts to establish a government independent of the Regency or the French took the form of rebellion, under the leadership of Miguel Hidalgo. Hidalgo was captured and executed in 1811, but a resistance movement continued, which declared independence from Spain in 1813. The Gutiérrez–Magee Expedition was a joint Tejanos-US volunteers expedition formed in Louisiana for Texas independence but was defeated in the Battle of Medina. In Central America, attempts at establishing juntas were also put down, but resulted in significantly less violence. The Caribbean islands, like the Philippines on the other side of the world, were relatively peaceful. Any plots to set up juntas were denounced to the authorities early enough to stop them before they gained widespread support.

=== Psychiatry === Acetylcysteine has been studied for major psychiatric disorders, including bipolar disorder, major depressive disorder, and schizophrenia. Preliminary research indicates N-acetylcysteine may be useful in treating obsessive-compulsive disorder, specific drug addictions (cocaine), drug-induced neuropathy, trichotillomania, excoriation disorder, and a certain form of epilepsy (progressive myoclonic). Other research has tested N-acetylcysteine in anxiety disorder, attention deficit hyperactivity disorder and mild traumatic brain injury, although its efficacy for these conditions remains unestablished.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

Network